AR109514A1 - Análogos de amilina - Google Patents

Análogos de amilina

Info

Publication number
AR109514A1
AR109514A1 ARP170102485A ARP170102485A AR109514A1 AR 109514 A1 AR109514 A1 AR 109514A1 AR P170102485 A ARP170102485 A AR P170102485A AR P170102485 A ARP170102485 A AR P170102485A AR 109514 A1 AR109514 A1 AR 109514A1
Authority
AR
Argentina
Prior art keywords
analogs
amiline
diabetes
disorders
treat
Prior art date
Application number
ARP170102485A
Other languages
English (en)
Inventor
Jesper Skodborg VILLADSEN
Henrik Kofoed Munch
Lise Giehm
Jesper Mosloff Mathiesen
Giacomo Fossati
Alexander Heim-Riether
Dieter Wolfgang Hamprecht
Original Assignee
Zealand Pharma As
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As
Publication of AR109514A1 publication Critical patent/AR109514A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente divulgación se refiere a análogos de amilina y su uso para tratar o prevenir varias enfermedades, afecciones o trastornos, que incluyen obesidad, ingesta excesiva de alimentos y enfermedades metabólicas asociadas tal como la diabetes, Los análogos pueden tener una buena estabilidad física y química, una buena solubilidad y una duración de acción prolongada y son muy adecuados para usar en forma de formulación líquida.
ARP170102485A 2016-09-09 2017-09-08 Análogos de amilina AR109514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16188024 2016-09-09

Publications (1)

Publication Number Publication Date
AR109514A1 true AR109514A1 (es) 2018-12-19

Family

ID=56990230

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102485A AR109514A1 (es) 2016-09-09 2017-09-08 Análogos de amilina

Country Status (26)

Country Link
US (4) US10071140B2 (es)
EP (2) EP3510044B1 (es)
JP (1) JP7064103B2 (es)
KR (1) KR102498393B1 (es)
CN (1) CN109863168B (es)
AR (1) AR109514A1 (es)
AU (1) AU2017322277B2 (es)
BR (1) BR112019004534A2 (es)
CA (1) CA3035958A1 (es)
CL (1) CL2019000575A1 (es)
CO (1) CO2019002159A2 (es)
DK (1) DK3510044T3 (es)
EA (1) EA201990360A1 (es)
ES (1) ES2901386T3 (es)
IL (1) IL264864B2 (es)
MA (1) MA46180A (es)
MX (1) MX2019002599A (es)
MY (1) MY197024A (es)
PE (1) PE20190963A1 (es)
PH (1) PH12019500474A1 (es)
SA (1) SA519401239B1 (es)
SG (1) SG11201901423XA (es)
TW (1) TWI784968B (es)
UA (1) UA123369C2 (es)
WO (1) WO2018046719A1 (es)
ZA (1) ZA201901253B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016232218B2 (en) * 2015-03-18 2020-09-10 Boehringer Ingelheim International Gmbh Amylin analogues
US10071140B2 (en) * 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2021094259A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
PE20231566A1 (es) 2020-08-07 2023-10-04 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
WO2023227133A1 (zh) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途
EP4319798A1 (en) 2022-05-30 2024-02-14 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DE69232064T2 (de) 1991-11-19 2002-03-28 Amylin Pharmaceuticals Inc Peptide als Amylin-Agonisten und ihre Verwendung
ZA946881B (en) 1993-09-07 1995-10-30 Amylin Pharmaceuticals Inc Methods for treating gastrointestinal motility
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
CA2206028C (en) 1997-06-04 2006-10-03 Frantisek Ziak Fitness-balance board
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
ATE409193T1 (de) 1999-03-17 2008-10-15 Novo Nordisk As Verfahren zur acylierung von peptiden und proteinen
EP1631308B1 (en) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
RU2385878C2 (ru) * 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
JP5703226B2 (ja) 2008-10-21 2015-04-15 ノヴォ ノルディスク アー／エス アミリン誘導体
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
EP2370459A1 (en) 2008-12-15 2011-10-05 Zealand Pharma A/S Glucagon analogues
EA020520B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
EP2504355B1 (en) 2009-11-25 2015-07-22 Novo Nordisk A/S Method for making polypeptides
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
MX2012014961A (es) 2010-06-24 2013-02-26 Zealand Pharma As Analogos de glucagon.
RU2669999C2 (ru) 2011-06-10 2018-10-17 Ново Нордиск А/С Полипептиды
EP2793931A2 (en) 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon analogues
ES2640285T3 (es) 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
UA122767C2 (uk) 2013-10-17 2021-01-06 Зіленд Фарма А/С Ацильований аналог глюкагону
DK3137494T3 (da) 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
AU2016232218B2 (en) * 2015-03-18 2020-09-10 Boehringer Ingelheim International Gmbh Amylin analogues
US10071140B2 (en) * 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same

Also Published As

Publication number Publication date
IL264864A (es) 2019-04-30
US10071140B2 (en) 2018-09-11
BR112019004534A2 (pt) 2019-06-25
TWI784968B (zh) 2022-12-01
CN109863168A (zh) 2019-06-07
PE20190963A1 (es) 2019-07-08
EP4074729A1 (en) 2022-10-19
CA3035958A1 (en) 2018-03-15
ES2901386T3 (es) 2022-03-22
IL264864B1 (en) 2023-06-01
WO2018046719A1 (en) 2018-03-15
IL264864B2 (en) 2023-10-01
US11382956B2 (en) 2022-07-12
CO2019002159A2 (es) 2019-07-31
JP2019534248A (ja) 2019-11-28
AU2017322277A1 (en) 2019-03-28
KR20190045333A (ko) 2019-05-02
PH12019500474A1 (en) 2019-08-05
MX2019002599A (es) 2019-09-18
US20200188485A1 (en) 2020-06-18
EA201990360A1 (ru) 2019-09-30
AU2017322277B2 (en) 2021-11-11
US20210346468A1 (en) 2021-11-11
SA519401239B1 (ar) 2023-07-09
KR102498393B1 (ko) 2023-02-13
MA46180A (fr) 2021-03-24
ZA201901253B (en) 2022-10-26
TW201811818A (zh) 2018-04-01
EP3510044B1 (en) 2021-11-24
CN109863168B (zh) 2023-04-18
MY197024A (en) 2023-05-22
UA123369C2 (uk) 2021-03-24
US20190134159A1 (en) 2019-05-09
JP7064103B2 (ja) 2022-05-10
CL2019000575A1 (es) 2019-05-10
DK3510044T3 (da) 2021-12-13
SG11201901423XA (en) 2019-03-28
US20180071366A1 (en) 2018-03-15
EP3510044A1 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
CO2019002159A2 (es) Análogos de amilina
CO2017008870A2 (es) Análogos de amilina
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CO2020001702A2 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
AR103350A1 (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
PE20171243A1 (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
DOP2016000076A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
CO2017007007A2 (es) Análogos de calcitonina
CL2016001167A1 (es) Uso de un implante bioerosionable para tratar enfermedades oculares.